Comparing the outcomes pimecrolimus and mometasone cream in treatment of childhood vitiligo

Comparing the outcomes of 1% pimecrolimus cream with 0.1% mometasone cream in treatment of childhood vitiligo in the face, neck and trunk

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230307057646N1

Enrollment

Registered

2023-05-19

Start date

2023-07-06

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo. Vitiligo

Interventions

Intervention 1: Intervention group: pimecrolimus 1% cream, topical use , twice a day for 2 months. Intervention 2: Intervention group: Mometasone 0.1% cream, topical use , daily.

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Vitiligo in less than 10 percent of body surface non-segmental vitiligo no history of allergic reaction to used drugs

Exclusion criteria

Exclusion criteria: pregnancy and lactating using other treatments for vitiligo lesions in last 6 months severe allergic reactions to used drugs

Design outcomes

Primary

Measure	Time frame
Visual Analogue Scale score of improvement according to the patients. Timepoint: 3 months after the initiation of the treatments. Method of measurement: patients score the improvement from 1-10.;Mean changes in lesions size. Timepoint: 2 and 3 months after the initiation of the treatment. Method of measurement: millimeter sensitive ruler.;Pigmentation improvement in the lesions according to 2 experts. Timepoint: 2 and 3 months after the initiation of the treatment. Method of measurement: 2 experts in dermatology scoring the improvement from 0 to 3.	—

Measure

Time frame

Visual Analogue Scale score of improvement according to the patients. Timepoint: 3 months after the initiation of the treatments. Method of measurement: patients score the improvement from 1-10.;Mean changes in lesions size. Timepoint: 2 and 3 months after the initiation of the treatment. Method of measurement: millimeter sensitive ruler.;Pigmentation improvement in the lesions according to 2 experts. Timepoint: 2 and 3 months after the initiation of the treatment. Method of measurement: 2 experts in dermatology scoring the improvement from 0 to 3.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSarah Seyedyousefi

Esfahan University of Medical Sciences

Sarah.syousefi@gmail.com+98 31 3630 5800

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026